news
Longevity AI, Clalit to refine heart disease, diabetes risk models
Longevity AI is partnering with Clalit Health Group's Meir Medical Center to recalibrate cardiovascular disease and Type 2 diabetes risk prediction models. They're using real-world data from Clalit's integrated healthcare system to make these models more accurate for personalized care.
Longevity AI is partnering with Clalit Health Group's Meir Medical Center to recalibrate cardiovascular disease and Type 2 diabetes risk prediction models. They're using real-world data from Clalit's integrated healthcare system to make these models more accurate for personalized care.
The architecture take
AI tackling heart disease and diabetes risk prediction? Smart. But the real story is recalibrating existing models with actual, longitudinal patient data. We've seen plenty of 'AI will fix everything' headlines, but this is about refinement, not reinvention. The outcome: more precise risk scores, which could actually change someone's day-to-day. If the algorithms get better at flagging who's truly at risk, it means earlier interventions and less wasted effort on those who aren't. It's a pragmatic use of AI – not predicting the future, but getting a sharper read on the current probability. Watch for how well these 'retrained' models generalize beyond Clalit's specific patient population. That's crunch time. Accuracy changes what you eat, how you move, and what meds you consider. That's a real-body impact.